News
Video
Helen Thackray, MD, provides a brief overview and highlights of the RESET clinical trial.
In an interview with Pharmacy Times, Helen Thackray, MD from GlycoMimetics, Inc. gave a quick overview and highlights of her study, called “Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis," which was presented at the 62nd ASH Annual Meeting and Exposition.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.